Wang, David http://orcid.org/0000-0001-5427-4961
Jackson, Chris
Hung, Noelyn
Hung, Tak
Kwan, Rudolf
Chan, Wing-Kai
Qin, Albert
Hughes-Medlicott, Natalie J.
Glue, Paul
Duffull, Stephen http://orcid.org/0000-0002-6545-9408
Funding for this research was provided by:
University of Otago (Doctoral Scholarship)
University of Otago
Article History
Received: 6 October 2023
Accepted: 8 March 2024
First Online: 19 March 2024
Declarations
:
: D.W. received the University of Otago Doctoral scholarship. T.H. is the owner of Zenith Technology Limited contracted to perform the Phase I trial reported by Athenex Inc. R.K. was the former Chief Medical Officer of Athenex Inc and owned shares in Athenex. W.K.C. was the former Direct of Clinical Trials of Athenex Inc and do not own shares in Athenex. N.H. is the medical director of Zenith Technology Limited. A.Q. is the Chief Medical Officer of PharmaEssentia Corporation. C.J., S.D., P.G., K.E. have no conflicts of interests to disclose.